University Of Southampton

New UK-created cancer therapies to be trialled, benefiting NHS patients through partnerships with pharma companies and universities. Innovations aim to transform treatment and launch globally significant Medtech products, driving economic growth in the UK's life sciences industry.

Researchers at the University of Southampton developed RI-AG03, a drug targeting both key areas of the Tau protein linked to Alzheimer’s, preventing Tau build-up in lab and fruit fly studies. This dual-targeting approach could lead to more effective treatments for neurodegenerative diseases.

A new drug, RI-AG03, targets two 'hotspots' on tau proteins to reduce neuron degeneration and tangling, potentially benefiting Alzheimer's treatment. It showed positive effects in fruit flies and human cells, extending fly lifespan by 35%. Designed using computational biology, RI-AG03 is less likely to interact with other proteins, minimizing side effects. Future tests on mice and clinical trials are planned.

A new Alzheimer’s drug, RI-AG03, targets both key areas of tau proteins, preventing their build-up in lab and fruit fly studies, potentially leading to more effective treatments.

NHS cancer patients to benefit from new partnerships with pharmaceutical companies and universities, aiming to spot cancer sooner through trials of AI and other technologies. This initiative could transform treatment and launch globally significant Medtech products, supported by £118 million in UKRI funding for five new health tech hubs. The UK's life sciences industry, already contributing £108 billion to the economy, is set to drive further investment and innovation in cancer treatment and diagnostics.

Researchers developed RI-AG03, a novel peptide inhibitor targeting tau protein aggregation in Alzheimer's disease, showing efficacy in fruit fly models and human-derived cells. The compound inhibits tau clumping at two 'hotspots,' potentially leading to more effective treatments for neurodegenerative diseases.

Scientists developed RI-AG03, a novel Alzheimer's drug targeting tau protein aggregation at two key sites, showing promise in cell and fruit fly studies. Collaboration among multiple institutions led to this breakthrough, potentially paving the way for more effective treatments.

Researchers developed RI-AG03, a peptide inhibitor targeting Tau protein aggregation hotspots, showing efficacy in preventing aggregation and extending lifespan in fruit fly models, with potential for Alzheimer’s treatment.

Researchers developed a drug, RI-AG03, targeting tau protein clumping in Alzheimer's disease, extending fruit fly lifespan and reducing tau aggregation in cells. Plans for rodent testing precede potential clinical trials, despite past failures of tau-based therapies.

New drug RI-AG03 targets tau protein to prevent Alzheimer’s-related neurodegeneration, inhibiting tau aggregation at two key regions. Preliminary tests on fruit flies and cells show promising results, with plans for rodent trials before clinical testing.